YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study

MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences
Inc. (NYSE Amex: YMI, TSX:YM), announced the conclusion of
dose-escalation in the Phase I portion of its Phase I/II clinical
trial of CYT387 at Mayo Clinic in patients with...